NCT00996892

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase Ib, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 178 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, Phase Ib dose-escalation study designed to assess the safety, tolerability and pharmacokinetics of oral dosing of cobimetinib and pictilisib administered in combination in patients with locally advanced or metastatic solid tumors.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	Cobimetinib	Repeated oral dosing.
DRUG	Pictilisib	Repeated oral dosing.

Timeline

• Start date: 2009-11-01
• Primary completion: 2014-03-01
• Completion: 2014-03-01
• First posted: 2009-10-16
• Last updated: 2016-12-30
• Results posted: 2016-12-30

Locations

6 sites across 1 country: United States